Redrawing therapeutic boundaries : microbiota and cancer


En Novembre 2021,  Jonathan Sholl et Thomas Pradeu publient un article “Redrawing therapeutic boundaries: microbiota and cancer“, qui fait la couverture de Trends in Cancer en  Février 2022!

Financé par BRIO,  Jonathan Sholl avait rejoint l’équipe de Thomas Pradeu au sein d’Immuno Concept en 2021.


Trends In Cancer, 2022 Feb

              Jonathan ShollGregory D Sepich-Poore Rob Knight Thomas Pradeu 





Abstract

The unexpected roles of the microbiota in cancer challenge explanations of carcinogenesis that focus on tumor-intrinsic properties. Most tumors contain bacteria and viruses, and the host’s proximal and distal microbiota influence both cancer incidence and therapeutic responsiveness. Continuing the history of cancer-microbe research, these findings raise a key question: to what extent is the microbiota relevant for clinical oncology? We approach this by critically evaluating three issues: how the microbiota provides a predictive biomarker of cancer growth and therapeutic responsiveness, the microbiota’s causal role(s) in cancer development, and how therapeutic manipulations of the microbiota improve patient outcomes in cancer. Clarifying the conceptual and empirical aspects of the cancer-associated microbiota can orient future research and guide its implementation in clinical oncology.

Keywords: biomarkers; cancer; causality; microbiota; network medicine; therapeutic modulation.

Conflict of interest statement

Declaration of interests G.D.S-P. and R.K. are inventors on a US patent application (PCT/US2019/059647) submitted by the Regents of the University of California and licensed by Micronoma; that application covers methods of diagnosing and treating cancer using microbial biomarkers in blood and cancer tissues. G.D.S-P. and R.K. are founders of and report stock interest in Micronoma. G.D.S-P. has filed several additional US patent applications on cancer microbiome diagnostics that are owned by the Regents of the University of California. R.K. additionally is a member of the scientific advisory board for GenCirq, holds an equity interest in GenCirq, and can receive reimbursements for expenses up to US $5000 per year.